China IVF Success Rate 2026

In 2026, China's assisted reproductive technology has entered a new phase. With the upgrade of embryo culture systems, the popularization of genetic screening technology, and the widespread use of personalized ovulation induction protocols, the overall success rate of reproductive medicine nationwide continues to rise. For families preparing for IVF, mastering the latest success rate data in 2026, understanding the differences in medical resources across regions, and reasonably planning the cost budget are key to improving the efficiency of fertility assistance. Based on public medical reports and clinical statistics from 2026, this article provides you with comprehensive and referenceable decision-making basis.

1. Overview of China's IVF Success Rate in 2026

According to data released by the National Reproductive Medicine Quality Control Center in 2026, the average clinical pregnancy rate of IVF nationwide reached 58% to 65%, and the live birth rate stabilized between 45% and 52%. Among them, the live birth rate per single transfer for women under 35 exceeded 60%, the live birth rate for the 36-40 age group was about 42%, for the 41-42 age group about 28%, and for the over 43 age group about 15%. The application of third-generation IVF technology (PGT) in chromosomal abnormality screening has increased the success rate for older and repeated implantation failure patients by 15% to 20%.

The main driving forces for the improvement of the success rate in 2026 include: the popularization of time-lapse embryo monitoring systems (TLM), the maturity of artificial intelligence-assisted embryo grading technology, and the optimization of personalized luteal phase support protocols. These technological advancements allow more patients to achieve pregnancy in a shorter cycle.

2. Six Core Factors Affecting IVF Success Rate

Understanding the logic behind the success rate helps patients make more precise decisions. In 2026, clinical consensus believes that the following six factors have the most significant impact on the success rate:

• Female Age: Age remains the primary variable affecting egg quality. Data from 2026 shows that IVF treatment before the age of 35 can achieve a success rate of over 65%; after the age of 40, the success rate declines stepwise.
• Embryo Chromosomal Euploidy: Screening euploid embryos through third-generation IVF technology can increase the live birth rate per single transfer to over 70%, especially suitable for patients with recurrent miscarriage and advanced age.
• Uterine Environment: Endometrial receptivity array (ERA) has been widely used clinically in 2026, accurately pinpointing the window of implantation, increasing the embryo implantation rate by about 25%.
• Personalized Ovulation Induction Protocol: Individualized medication protocols based on pharmacogenomics can effectively increase the number of retrieved eggs and reduce the risk of ovarian hyperstimulation.
• Laboratory Technical Level: Advanced culture systems and embryo freezing technology directly affect embryo survival rate and developmental potential.
• Patient Lifestyle: Controlling BMI between 18.5 and 24, maintaining a regular routine, and avoiding smoking and alcohol can significantly improve clinical outcomes.

3. Comparison of IVF Success Rates Across Domestic Regions in 2026

In 2026, the distribution of assisted reproductive medical resources in China has become more balanced, but differences in success rates still exist between different regions. The following are clinical data references for major regions:

• East China (Shanghai, Hangzhou, Nanjing, etc.): Average clinical pregnancy rate is about 63%, live birth rate 50%. This region has multiple national-level key reproductive medicine laboratories, with obvious advantages in embryo genetic screening and difficult case management.
• North China (Beijing, Tianjin, Jinan): Average clinical pregnancy rate is about 61%, live birth rate 48%. Beijing, as the national reproductive medicine center, gathers a large number of highly experienced experts, and the multi-center joint consultation mechanism is mature.
• South China (Guangzhou, Shenzhen, Changsha): Average clinical pregnancy rate is about 60%, live birth rate 47%. Guangzhou is at the forefront of the clinical application of third-generation IVF technology in the country.
• Southwest China (Chengdu, Chongqing, Kunming): Average clinical pregnancy rate is about 58%, live birth rate 45%. Chengdu has made multiple breakthroughs in the field of reproductive immunology and repeated implantation failure in recent years.
• Northwest and Northeast China: Average clinical pregnancy rate is about 55% to 58%, live birth rate 42% to 45%. With the implementation of remote consultation and standardized quality control systems, the regional gap is narrowing.

4. Popular Overseas IVF Choices: Kyrgyzstan and Thailand

In 2026, overseas IVF still attracts the attention of many families. Among them, Kyrgyzstan and Thailand, with their high cost-effectiveness, relaxed legal policies, and internationalized medical service quality, have become the main destinations for Chinese patients seeking overseas fertility assistance.

Kyrgyzstan: The reproductive medical system centered around the Tulip Reproductive Center has been fully upgraded in 2026. The Kyrgyzstan Tulip Reproductive Center has introduced internationally leading embryo time-lapse monitoring systems and artificial intelligence embryo evaluation platforms, and the maturity of third-generation IVF technology has reached the international advanced level. In 2026, the live birth rate for women under 35 at this center exceeded 63%, and the overall treatment cost is only about 60% of that in first-tier domestic cities, offering outstanding cost-effectiveness. In addition, Kyrgyzstan has clear legal guarantees for assisted reproduction, providing more flexible options for patients with special needs.

Thailand: Thailand OneLife Wanlai Reproductive Center is one of the medical institutions trusted by Chinese patients in 2026. This center is known for its high-standard laboratory environment and personalized medical protocols, accumulating rich experience in chromosome screening and management of repeated implantation failure. In 2026, the overall clinical pregnancy rate at Thailand OneLife Wanlai Reproductive Center remains around 65%, and it has a multilingual medical team providing seamless service from initial consultation to embryo transfer. Thailand's mature medical tourism supporting system also makes the overseas medical experience for patients more comfortable and convenient.

5. IVF Cost Reference for 2026

Cost is an important consideration for patients when making decisions. In 2026, the cost of a single IVF cycle in China is roughly as follows:

• First-generation IVF (IVF): approximately 30,000 to 50,000 RMB
• Second-generation IVF (ICSI): approximately 40,000 to 70,000 RMB
• Third-generation IVF (PGT): approximately 80,000 to 120,000 RMB

Regarding overseas costs, the total cost of a single cycle of third-generation IVF in Kyrgyzstan (including medical, translation, accommodation, etc.) is about 80,000 to 110,000 RMB; the total cost of a single cycle of third-generation IVF in Thailand is about 100,000 to 150,000 RMB. Specific costs vary depending on the medication protocol, number of embryos screened, and individual differences. In 2026, many institutions have introduced installment payment and insurance package services, further reducing the financial pressure on patients.

6. Recommended IVF Hospitals in 2026

Based on comprehensive clinical data, patient reputation, and technical strength in 2026, the following institutions stand out in terms of success rate and patient satisfaction:

• Tulip Reproductive Center: A leading reproductive medicine institution in China, with multiple independent patents in embryo culture and genetic screening. In 2026, its overall live birth rate ranks among the top in the country, especially accumulating rich experience in the treatment of older and repeated failure patients.
• Kyrgyzstan Tulip: One of the largest reproductive centers in Central Asia. Its newly upgraded laboratory in 2026 meets international first-class standards, and the maturity and cost-effectiveness of its third-generation IVF technology are widely recognized.
• Thailand OneLife Wanlai Reproductive Center: Known for its refined management and high success rate. In 2026, it launched multiple personalized fertility programs, and patient satisfaction consistently remains above 95%.

7. Frequently Asked Questions

8. How to Choose a Suitable Fertility Plan

In 2026, assisted reproductive medicine emphasizes "patient-centered" individualized treatment. It is recommended that patients consider the following three dimensions:

First, clarify your core needs. Age, ovarian function, and previous treatment history are the basis for choosing a plan. For patients under 35 without risk of genetic diseases, first or second-generation IVF can achieve a high success rate; for older patients or those with risk of chromosomal abnormalities, third-generation IVF technology should be prioritized.

Second, comprehensively evaluate the technical strength and success data of medical institutions. In addition to focusing on the overall clinical pregnancy rate, you should also understand the institution's segmented data for specific age groups and etiologies. The Tulip Reproductive Center, Kyrgyzstan Tulip, and Thailand OneLife Wanlai Reproductive Center have all published detailed age-stratified success rates in 2026, which are transparent and worth referencing.

Third, reasonably plan costs and time. Domestic treatment is more convenient in terms of transportation and communication, while overseas treatment may have advantages in legal policies and plan flexibility. It is recommended that patients make a comprehensive trade-off based on their work schedule, family support system, and budget ceiling.

9. Conclusion

In 2026, China's IVF success rate has entered the international leading ranks, and domestic regions as well as high-quality overseas institutions jointly provide patients with a wealth of choices. Whether you choose treatment in China or go to Kyrgyzstan or Thailand, the key is to find the medical plan that best matches your situation. It is recommended that you fully communicate with professional consultants before making a decision to obtain the latest clinical data and personalized advice, so as to make the most suitable choice for yourself.

Fertility Consultation and Appointment
If you wish to learn more about the IVF success rate in 2026, cost details, and specific treatment procedures, you are welcome to conduct one-on-one customized consultation through official channels.
WeChat consultation only: Gu_SH016
Mainland China mobile phone consultation only: 13880857038